It was supposed to be a “good-news” day for Indianapolis-based biotech Point Biopharma Global Inc. Instead, the company saw its stock get battered Monday, losing as much as 38% of its value, after it ...

Point Biopharma is a clinical-stage company that focuses on therapies that bind to cells to fight cancer. On Tuesday, Eli Lilly agreed to pay roughly $1.4 billion to buy the company. The deal, set at ...

The company's innovative product pipeline and exclusive CanSEEK technology offer groundbreaking cancer treatments that address unmet clinical needs, positioning POINT for leadership in the biopharma ...

Shares of Indianapolis-based Point Biopharma fell more than 11% Monday after the company announced results of a clinical trial for its lead compound that fell short of analysts’ expectations. The ...

Eli Lilly’s buying spree continues with the purchase of Point Biopharma for $1.4 billion, which was announced Tuesday morning. Per terms of the agreement, the pharma giant is paying $12.50 per share ...

POINT Biopharma has two therapies in Phase 3 development with fast track designation, which creates the potential for positive catalysts as early as this year. Positive results from the Phase 2 study ...

On Tuesday, Eli Lilly agreed to acquire Point Biopharma for $12.50 per share in cash -- an 87% premium from Monday's close. The deal isn't subject to financing conditions, but still requires a license ...

A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...

INDIANAPOLIS, Feb. 25, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to ...

Point Biopharma focuses on oncology therapies. The company's lead therapy is PNT2002 to treat prostate cancer. Point Biopharma is a clinical-stage company that focuses on therapies that bind to cells ...